Literature DB >> 30196207

Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.

Jinlei Bian1, Jie Ren2, Yongren Li3, Jubo Wang2, Xi Xu2, Yifan Feng2, Hui Tang2, Yajing Wang4, Zhiyu Li5.   

Abstract

Wogonin is a natural product isolated from the Scutellaria baicalensis and has been proved to be a potent and selective inhibitor of CDK9. Using this scaffold, we designed and synthesized a series of proteolysis targeting chimeras (PROTACs) targeting CDK9 by recruiting ubiquitin E3 ligase cereblon (CRBN). For constructing diverse Wogonin-based PROTACs, a "click chemistry" approach was employed for the synthesis of CDK9-targeting PROTACs. The results of western blotting assays showed that compounds containing triazole group in the linker could selectively downregulate the intracellular CDK9 level. Among these compounds, 11c could selectively degrade CDK9 in a concentration-dependent manner. In addition, the application of the proteasome inhibitor MG132 and CRBN siRNA silencing confirmed that 11c could promote the proteasome-dependent and CRBN-dependent degradation. Consistent with the degradation of the CDK9 protein, 11c selectively inhibits proliferation of CDK9-overexpressed cancer cells. Thus, our Wogonin-based PROTAC would be an efficient probe that induces the degradation of CDK9.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antitumor; CDK9; Click Chemistry; PROTAC; Wogonin

Mesh:

Substances:

Year:  2018        PMID: 30196207     DOI: 10.1016/j.bioorg.2018.08.028

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  29 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 2.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 3.  Targeted protein degradation: elements of PROTAC design.

Authors:  Stacey-Lynn Paiva; Craig M Crews
Journal:  Curr Opin Chem Biol       Date:  2019-04-17       Impact factor: 8.822

Review 4.  Cereblon: promise and challenges for combating human diseases.

Authors:  Hyoung Kyu Kim; Jung Eun Seol; Sang Woo Ahn; Seungje Jeon; Chul-Seung Park; Jin Han
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 3.657

Review 5.  CDK9 inhibitors in cancer research.

Authors:  Zhi Huang; Tianqi Wang; Cheng Wang; Yan Fan
Journal:  RSC Med Chem       Date:  2022-04-20

Review 6.  Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?

Authors:  Chen-Xi Zhao; Chen-Ming Zeng; Ke Wang; Qiao-Jun He; Bo Yang; Fan-Fan Zhou; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-06-29       Impact factor: 6.150

7.  Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta.

Authors:  Nan Bai; Sven A Miller; Grigorii V Andrianov; Max Yates; Palani Kirubakaran; John Karanicolas
Journal:  J Chem Inf Model       Date:  2021-02-24       Impact factor: 4.956

8.  Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.

Authors:  Hannah M King; Sandeep Rana; Sydney P Kubica; Jayapal Reddy Mallareddy; Smitha Kizhake; Edward L Ezell; Muhammad Zahid; Michael J Naldrett; Sophie Alvarez; Henry C-H Law; Nicholas T Woods; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2021-04-23       Impact factor: 2.940

Review 9.  Cell cycle on the crossroad of tumorigenesis and cancer therapy.

Authors:  Jing Liu; Yunhua Peng; Wenyi Wei
Journal:  Trends Cell Biol       Date:  2021-07-22       Impact factor: 20.808

Review 10.  Targeting Protein Kinases Degradation by PROTACs.

Authors:  Fei Yu; Ming Cai; Liang Shao; Jihong Zhang
Journal:  Front Chem       Date:  2021-06-30       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.